Skip to main content
Cardiovascular DiseasesDrugPhase 4

What this study is

This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.

What's being tested

  • Losartan

    Intervention · DRUG

    50 mg tablets taken orally

  • Placebo

    Intervention · DRUG

    Tablets taken orally

Study details

Official title
Occult Cardiovascular Disease With Chronic Exposure to Secondhand Tobacco Smoke
Sponsor
University of California, San Francisco
Conditions
Cardiovascular Diseases · Hypertension
Enrolling
100 people
Starts
2021-03-30
Est. completion
2026-12-31
Design
Quadruple-blind, randomized, crossover, Phase 4
Record
View on ClinicalTrials.gov ↗